Insulet (NASDAQ:PODD) Hits New 52-Week Low – Here’s Why

Insulet Corporation (NASDAQ:PODD) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $216.05 and last traded at $216.1160, with a volume of 585871 shares. The stock had previously closed at $225.50.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. dropped their price target on Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a research report on Thursday, February 19th. Truist Financial decreased their price objective on Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a report on Thursday, February 19th. UBS Group reiterated a “buy” rating on shares of Insulet in a report on Thursday, December 18th. The Goldman Sachs Group cut their target price on shares of Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $354.24.

Insulet Price Performance

The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The firm has a market cap of $14.66 billion, a PE ratio of 59.49, a price-to-earnings-growth ratio of 1.29 and a beta of 1.42. The stock has a 50 day moving average price of $247.33 and a two-hundred day moving average price of $290.09.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. Insulet’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the business earned $1.15 EPS. As a group, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently bought and sold shares of PODD. Larson Financial Group LLC raised its holdings in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in Insulet during the fourth quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in Insulet during the fourth quarter valued at approximately $28,000. DV Equities LLC acquired a new position in Insulet in the fourth quarter valued at approximately $28,000. Finally, MV Capital Management Inc. acquired a new position in Insulet in the fourth quarter valued at approximately $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.